Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial

This study is a randomized, open-label, multicenter exploratory research aiming to evaluate the efficacy and safety of Adebrelimab in combination with chemotherapy (etoposide and platinum-based therapy) as neoadjuvant treatment for resectable stage I-IIIB (stage IIIB limited to T1-4N1-2M0) small cell lung cancer (SCLC). The study is primarily conducted at Tangdu Hospital of the Fourth Military Medical University. A total of 104 patients with stage IA-IIIB SCLC (stage IIIB limited to T1-4N1-2M0) will be enrolled and randomized 1:1 to receive either Adebrelimab plus chemotherapy or chemotherapy

Trial Details

NCT ID
NCT06485544
Phase
PHASE2
Sponsor
Tang-Du Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Adebrelimab + Etoposide + Platinum-based Therapy
  • Etoposide + Platinum-based Therapy
Locations (sample)
  • Xi'an, Shannxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Age between 18 and 75 years, inclusive, with no restriction on gender.
  • ECOG performance status of 0-1.
  • Histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC).
  • According to the 8th edition of AJCC staging, participants must have resectable or potentially resectable stage I-IIIB (T1-4N0-2M0) SCLC.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →